Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity.

Salmon VE, Hewlett S, Walsh NE, Kirwan JR, Morris M, Urban M, Cramp F.

BMC Musculoskelet Disord. 2019 May 4;20(1):194. doi: 10.1186/s12891-019-2558-4.

2.

Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT).

Hewlett S, Almeida C, Ambler N, Blair PS, Choy EH, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan JR, Plummer Z, Rooke C, Thorn J, Turner N, Pollock J; RAFT Study Group.

Ann Rheum Dis. 2019 Apr;78(4):465-472. doi: 10.1136/annrheumdis-2018-214469. Epub 2019 Feb 6.

3.

Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients.

Gossec L, Kirwan JR, de Wit M, Balanescu A, Gaujoux-Viala C, Guillemin F, Rat AC, Saraux A, Fautrel B, Kvien TK, Dougados M; RAID investigators.

Clin Rheumatol. 2018 Jun;37(6):1503-1510. doi: 10.1007/s10067-018-3998-1. Epub 2018 Feb 21.

PMID:
29468340
4.

Author Response: Patient Engagement.

Frank L, de Wit M, Kirwan JR, Guillemin F, Bartlett SJ.

Value Health. 2017 Dec;20(10):1433. doi: 10.1016/j.jval.2017.10.010. No abstract available.

5.

Coping Strategies, Psychological Impact, and Support Preferences of Men With Rheumatoid Arthritis: A Multicenter Survey.

Flurey CA, Hewlett S, Rodham K, White A, Noddings R, Kirwan JR.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):851-860. doi: 10.1002/acr.23422. Epub 2018 Apr 16.

6.

Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients.

Ferreira RJO, Dougados M, Kirwan JR, Duarte C, de Wit M, Soubrier M, Fautrel B, Kvien TK, da Silva JAP, Gossec L; CoimbRA investigators, RAID investigators and COMEDRA investigators.

Rheumatology (Oxford). 2017 Sep 1;56(9):1573-1578. doi: 10.1093/rheumatology/kex211.

PMID:
28859325
7.

Is There a Renaissance of Glucocorticoids in Rheumatoid Arthritis?

Kirwan JR, Gunasekera W.

Clin Pharmacol Ther. 2017 Oct;102(4):574-577. doi: 10.1002/cpt.753. Epub 2017 Aug 7.

PMID:
28783220
8.

Development and testing of candidate items for inclusion in a new rheumatoid arthritis stiffness patient-reported outcome measure.

Halls S, Dures E, Kirwan JR, Pollock J, Baker G, Edmunds A, Hewlett S.

Rheumatology (Oxford). 2018 Feb 1;57(2):263-272. doi: 10.1093/rheumatology/kex085.

PMID:
28407140
9.

Emerging Guidelines for Patient Engagement in Research.

Kirwan JR, de Wit M, Frank L, Haywood KL, Salek S, Brace-McDonnell S, Lyddiatt A, Barbic SP, Alonso J, Guillemin F, Bartlett SJ.

Value Health. 2017 Mar;20(3):481-486. doi: 10.1016/j.jval.2016.10.003. Epub 2016 Nov 17.

10.

Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group.

Halls S, Sinnathurai P, Hewlett S, Mackie SL, March L, Bartlett SJ, Bingham CO 3rd, Alten R, Campbell I, Hill CL, Holt RJ, Hughes R, Kirwan JR, Leong AL, Leung YY, Lyddiatt A, Neill L, Orbai AM.

J Rheumatol. 2017 Dec;44(12):1904-1910. doi: 10.3899/jrheum.161073. Epub 2016 Dec 15.

11.

Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT).

de Wit M, Kirwan JR, Tugwell P, Beaton D, Boers M, Brooks P, Collins S, Conaghan PG, D'Agostino MA, Hofstetter C, Hughes R, Leong A, Lyddiatt A, March L, May J, Montie P, Richards P, Simon LS, Singh JA, Strand V, Voshaar M, Bingham CO 3rd, Gossec L.

Patient. 2017 Apr;10(2):141-152. doi: 10.1007/s40271-016-0198-4.

12.

Identifying different typologies of experiences and coping strategies in men with rheumatoid arthritis: a Q-methodology study.

Flurey CA, Hewlett S, Rodham K, White A, Noddings R, Kirwan JR.

BMJ Open. 2016 Oct 3;6(10):e012051. doi: 10.1136/bmjopen-2016-012051.

13.

Rheumatoid arthritis: previously untreated early disease.

Gunasekera WM, Kirwan JR.

BMJ Clin Evid. 2016 Aug 1;2016. pii: 1124. Review.

14.

"You Obviously Just Have to Put on a Brave Face": A Qualitative Study of the Experiences and Coping Styles of Men With Rheumatoid Arthritis.

Flurey CA, Hewlett S, Rodham K, White A, Noddings R, Kirwan JR.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):330-337. doi: 10.1002/acr.22951.

15.

Biologic interventions for fatigue in rheumatoid arthritis.

Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, Pollock J, Christensen R.

Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008334. doi: 10.1002/14651858.CD008334.pub2. Review.

PMID:
27271314
16.

Commentary: Patients as Partners: Building on the Experience of Outcome Measures in Rheumatology.

Kirwan JR, de Wit MP, Bingham CO 3rd, Leong A, Richards P, Tugwell P, Voshaar M, Gossec L; Outcome Measures in Rheumatology Executive Committee.

Arthritis Rheumatol. 2016 Jun;68(6):1334-6. doi: 10.1002/art.39678. No abstract available.

17.

Outcome Measures in Polymyalgia Rheumatica. A Systematic Review.

Duarte C, Ferreira RJ, Mackie SL, Kirwan JR, Pereira da Silva JA; OMERACT Polymyalgia Rheumatica Special Interest Group.

J Rheumatol. 2015 Dec;42(12):2503-11. doi: 10.3899/jrheum.150515. Epub 2015 Nov 15. Review.

PMID:
26568600
18.

Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.

Helliwell T, Brouwer E, Pease CT, Hughes R, Hill CL, Neill LM, Halls S, Simon LS, Mallen CD, Boers M, Kirwan JR, Mackie SL.

J Rheumatol. 2016 Jan;43(1):182-6. doi: 10.3899/jrheum.141179. Epub 2015 Nov 15. Review.

19.

The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates.

Flurey CA, Kirwan JR, Hadridge P, Richards P, Grosskleg S, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1982-1992. doi: 10.3899/jrheum.150113. Epub 2015 Aug 15.

PMID:
26276970
20.

Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop.

Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, Stevens R, Strand V, Suarez-Almazor ME, Tugwell P, Wells GA.

J Rheumatol. 2015 Oct;42(10):1962-1970. doi: 10.3899/jrheum.141440. Epub 2015 May 15.

PMID:
25979719
21.

Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP.

Cheung PP, de Wit M, Bingham CO 3rd, Kirwan JR, Leong A, March LM, Montie P, Scholte-Voshaar M, Gossec L.

J Rheumatol. 2016 Jan;43(1):187-93. doi: 10.3899/jrheum.141011. Epub 2015 Apr 15. Review.

PMID:
25877496
22.

Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12.

van Tuyl LH, Sadlonova M, Davis B, Flurey C, Goel N, Hewlett SE, Hill CL, Hoogland W, Kirwan JR, van Schaardenburg D, Scholte-Voshaar M, Smolen JS, Stamm T, Wells GA, Boers M.

J Rheumatol. 2016 Jan;43(1):203-7. doi: 10.3899/jrheum.141113. Epub 2015 Feb 15. Review.

PMID:
25684772
23.

Updating the OMERACT filter at OMERACT 11.

Kirwan JR, Boers M, Tugwell P.

J Rheumatol. 2014 May;41(5):975-7. doi: 10.3899/jrheum.131306.

PMID:
24788466
24.

Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.

Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO 3rd, Choy E, Conaghan PG, Dougados M, Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewé RB, Mease PJ, Østergaard M, Simon L, Singh JA, Strand V, Wells G.

J Rheumatol. 2014 May;41(5):1000-4. doi: 10.3899/jrheum.131310. Epub 2014 Apr 1.

25.

Updating the OMERACT filter: discrimination and feasibility.

Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO 3rd, Boonen A, Brooks P, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Gossec L, Guillemin F, Helliwell P, Hewlett S, Kvien TK, Landewé RB, March L, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, van der Heijde DM.

J Rheumatol. 2014 May;41(5):1005-10. doi: 10.3899/jrheum.131311. Epub 2014 Apr 1.

26.

Updating the OMERACT filter: core areas as a basis for defining core outcome sets.

Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO 3rd, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, van der Heijde DM, Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2014 May;41(5):994-9. doi: 10.3899/jrheum.131309. Epub 2014 Mar 15.

27.

Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.

Boers M, Idzerda L, Kirwan JR, Beaton D, Escorpizo R, Boonen A, Magasi S, Sinha I, Stucki G, Tugwell P.

J Rheumatol. 2014 May;41(5):978-85. doi: 10.3899/jrheum.131307. Epub 2014 Mar 1.

PMID:
24584922
28.

Updating the OMERACT filter: implications for patient-reported outcomes.

Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikaï E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L.

J Rheumatol. 2014 May;41(5):1011-5. doi: 10.3899/jrheum.131312. Epub 2014 Mar 1.

PMID:
24584919
29.

How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.

Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO 3rd, Brooks PM, Landewé R, March L, Simon L, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2014 May;41(5):1025-30. doi: 10.3899/jrheum.131314. Epub 2014 Mar 1.

PMID:
24584913
30.

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, Conaghan PG, Bingham CO 3rd, Brooks P, Landewé R, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Clin Epidemiol. 2014 Jul;67(7):745-53. doi: 10.1016/j.jclinepi.2013.11.013. Epub 2014 Feb 28.

31.

Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, Morris M, Pease CT, Sherman JW, Simon LS, Walsh M, Westhovens R, Zakout S, Kirwan JR.

J Rheumatol. 2014 Apr;41(4):819-23. doi: 10.3899/jrheum.131254. Epub 2014 Feb 1. Review.

PMID:
24488422
32.

The intelligent use of systemic glucocorticoids in rheumatoid arthritis.

Mercieca C, Kirwan JR.

Expert Rev Clin Immunol. 2014 Jan;10(1):143-57. doi: 10.1586/1744666X.2014.864236. Epub 2013 Dec 2. Review.

PMID:
24308837
33.

Biological treatment in rheumatoid arthritis: when to stop?

Kirwan JR, Boers M.

Lancet. 2014 Jan 25;383(9914):288-9. doi: 10.1016/S0140-6736(13)61941-8. Epub 2013 Oct 26. No abstract available.

PMID:
24168959
34.

Non-pharmacological interventions for fatigue in rheumatoid arthritis.

Cramp F, Hewlett S, Almeida C, Kirwan JR, Choy EH, Chalder T, Pollock J, Christensen R.

Cochrane Database Syst Rev. 2013 Aug 23;(8):CD008322. doi: 10.1002/14651858.CD008322.pub2. Review.

PMID:
23975674
35.

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW.

Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19.

36.

Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales.

Dures EK, Hewlett SE, Cramp FA, Greenwood R, Nicklin JK, Urban M, Kirwan JR.

Rheumatology (Oxford). 2013 Oct;52(10):1832-9. doi: 10.1093/rheumatology/ket218. Epub 2013 Jul 9.

PMID:
23838026
37.

Using actigraphy to measure sleep patterns in rheumatoid arthritis: a pilot study in patients taking night-time prednisone.

Clarke LL, Wilson S, Kirwan JR.

Musculoskeletal Care. 2013 Sep;11(3):179-85. doi: 10.1002/msc.1052. Epub 2013 May 20.

38.

Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis.

Derendorf H, Ruebsamen K, Clarke L, Schaeffler A, Kirwan JR.

J Clin Pharmacol. 2013 Mar;53(3):326-33. doi: 10.1177/0091270012444315. Epub 2013 Jan 24.

PMID:
23444285
39.

Personality correlates of self-employed small business owners' success.

Owens KS, Kirwan JR, Lounsbury JW, Levy JJ, Gibson LW.

Work. 2013;45(1):73-85. doi: 10.3233/WOR-121536.

PMID:
23241705
40.

Our approach to the diagnosis and treatment of polymyalgia rheumatica and giant cell (temporal) arteritis.

Quick V, Kirwan JR.

J R Coll Physicians Edinb. 2012;42(4):341-9. doi: 10.4997/JRCPE.2012.413.

PMID:
23240123
41.

American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.

Boers M, Kirwan JR, Bijlsma JW.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622. doi: 10.1002/acr.21770. No abstract available.

42.

Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis.

Kirwan JR, Buttgereit F.

Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv14-20. doi: 10.1093/rheumatology/kes085. Review.

PMID:
22685271
43.

Combination therapy including glucocorticoids: the new gold standard for early treatment in rheumatoid arthritis?

Kirwan JR.

Ann Intern Med. 2012 Mar 6;156(5):390-1. doi: 10.7326/0003-4819-156-5-201203060-00014. No abstract available.

PMID:
22393135
44.

OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health.

Kirwan JR, Boonen A, Harrison MJ, Hewlett SE, Wells GA, Singh JA, Furst DE, Dworkin RH.

J Rheumatol. 2011 Aug;38(8):1728-34. doi: 10.3899/jrheum.110393.

PMID:
21807793
45.

It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10.

Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, Dougados M.

J Rheumatol. 2011 Aug;38(8):1720-7. doi: 10.3899/jrheum.110392.

PMID:
21807792
46.

Patient perspective: choosing or developing instruments.

Kirwan JR, Fries JF, Hewlett S, Osborne RH.

J Rheumatol. 2011 Aug;38(8):1716-9. doi: 10.3899/jrheum.110390.

PMID:
21807791
47.

Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes.

Kirwan JR, Fries JF, Hewlett SE, Osborne RH, Newman S, Ciciriello S, van de Laar MA, Dures E, Minnock P, Heiberg T, Sanderson TC, Flurey CA, Leong AL, Montie P, Richards P.

J Rheumatol. 2011 Aug;38(8):1711-5. doi: 10.3899/jrheum.110391.

PMID:
21807790
48.

Domains selection for patient-reported outcomes: current activities and options for future methods.

Tugwell PS, Petersson IF, Boers M, Gossec L, Kirwan JR, Rader T, Sanderson TC, van de Laar MA, Ueffing E, Witter JP.

J Rheumatol. 2011 Aug;38(8):1702-10. doi: 10.3899/jrheum.110389.

PMID:
21807789
49.

Overview of the patient perspective at OMERACT 10--conceptualizing methods for developing patient-reported outcomes.

Kirwan JR, Tugwell PS.

J Rheumatol. 2011 Aug;38(8):1699-701. doi: 10.3899/jrheum.110388.

PMID:
21807788
50.

Effects of neurofibromatosis type 1 on children's development.

Haynes NM, Kirwan JR, McCrohan K.

Soc Work Public Health. 2011;26(4):444-53. doi: 10.1080/19371918.2011.579498.

PMID:
21707352

Supplemental Content

Loading ...
Support Center